EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

PROTACs in Ovarian Cancer: Current Advancements and Future Perspectives

Makenzie Vorderbruggen, Carlos A Velázquez-Martínez iD, Amarnath Natarajan iD, Adam R Karpf iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25105067 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Makenzie Vorderbruggen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Eppley Institute for Research in Cancer, University of Nebraska Medical Center, Omaha, NE 68198-6805, USA. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Proteolysis, Antineoplastic Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 121 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ovarian cancer is the deadliest gynecologic malignancy. The majority of patients diagnosed with advanced ovarian cancer will relapse, at which point additional therapies can be administered but, for the most part, these are not curative. As such, a need exists for the development of novel therapeutic options for ovarian cancer patients. Research in the field of targeted protein degradation (TPD) through the use of proteolysis-targeting chimeras (PROTACs) has significantly increased in recent years. The ability of PROTACs to target proteins of interest (POI) for degradation, overcoming limitations such as the incomplete inhibition of POI function and the development of resistance seen with other inhibitors, is of particular interest in cancer research, including ovarian cancer research. This review provides a synopsis of PROTACs tested in ovarian cancer models and highlights PROTACs characterized in other types of cancers with potential high utility in ovarian cancer. Finally, we discuss methods that will help to enable the selective delivery of PROTACs to ovarian cancer and improve the pharmacodynamic properties of these agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsProteolysisAntineoplastic AgentsHumansFemaleAnimalsMolecular Targeted TherapyProteolysis Targeting Chimera

Stichwörter der Autor:innen

PROTAChigh-grade serous ovarian cancerovarian cancertargeted protein degradation

Substanzen

Antineoplastic AgentsProteolysis Targeting Chimera

Autor:innen und Institutionen

  • Eppley Institute for Research in Cancer, University of Nebraska Medical Center, Omaha, NE 68198-6805, USA.
  • Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198-6805, USA.
  • Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G 2E1, Canada.

ORCID-Profile: Carlos A Velázquez-Martínez, Amarnath Natarajan, Adam R Karpf

Förderung

  • NCI NIH HHS

Zitieren

APA

Vorderbruggen, M., Velázquez-Martínez, C. A., Natarajan, A., & Karpf, A. R. (2024). PROTACs in Ovarian Cancer: Current Advancements and Future Perspectives. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25105067

Vancouver

Vorderbruggen M, Velázquez-Martínez CA, Natarajan A, Karpf AR. PROTACs in Ovarian Cancer: Current Advancements and Future Perspectives. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25105067

BibTeX
@article{Vorderbruggen2024,
  author = {Vorderbruggen, Makenzie and Velázquez-Martínez, Carlos A and Natarajan, Amarnath and Karpf, Adam R},
  title = {PROTACs in Ovarian Cancer: Current Advancements and Future Perspectives},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25105067}
}
Kostenlos starten →